RxDoctor Payments Data

Brian Rubin, MD

Internal Medicine · Bronx, NYNPI 1871678631

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 15 payments — averaging $111.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • Teva Pharmaceuticals USA, Inc.$237
  • Sanofi$180
  • Tepha Inc$173
  • Amarin Pharma, Inc.$132
  • Amgen$125
  • plus $476 from 4 others

What the payments were for

  • Speaking & faculty fees$18011%
  • Food & beverage$1,49689%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$25,307
Medicare patients
137
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$122,474
JanuviaSitagliptin Phosphate116$76,822
JardianceEmpagliflozin75$60,926
EliquisApixaban68$53,338
RybelsusSemaglutide16$22,845
FarxigaDapagliflozin Propanediol19$20,401
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$15,368
TrulicityDulaglutide12$14,603
EntrestoSacubitril/Valsartan20$13,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,165
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,494
Albuterol Sulfate HfaAlbuterol Sulfate261$8,517
Nifedipine ErNifedipine234$4,759
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,367
Atorvastatin Calcium355$3,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$354$145,320132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →